Everything below concerns certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-22. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Analysis of clinical trial results that includes all data from participants in the groups to which they were randomized even if they never received the treatment. (NLM) The principle that asserts that the effect of a treatment policy can be best assessed by evaluating on the basis of the intention to treat a subject (i.e. the planned treatment regimen) rather than the actual treatment given. It has the consequence that subjects allocated to a treatment group should be followed up, assessed and analysed as members of that group irrespective of their compliance to the planned course of treatment. (ICH E9) Interaction (Qualitative & Quantitative)
=== Relationship === Rose's parents forbade their daughter from continuing to date Fred, but she defied their wishes, prompting them to visit Gloucestershire's social services agency to explain that their 15-year-old daughter was having a sexual relationship with an older man, and that they had heard rumours that she had begun to engage in prostitution at Fred's caravan. In response, Rose was placed in a home for troubled teenagers in Cheltenham in August 1969, and only permitted to leave under controlled conditions. When allowed to return home to visit her parents at weekends, Rose almost invariably took the opportunity to visit Fred. On her 16th birthday, Rose left the home for troubled teenagers to return to her parents while Fred was serving a thirty-day sentence for theft and unpaid fines. Upon his release, Rose left her parents' home to move into a flat in Cheltenham with Fred. Shortly thereafter, Fred collected Charmaine and Anne Marie from social services. Rose's father made one final effort to prevent his daughter from seeing Fred, and Rose was examined by a police surgeon in February 1970, who confirmed she was pregnant. In response, Rose was again placed into care but was discharged on 6 March on the understanding she would terminate her pregnancy and return to her family. Instead, Rose opted to live with Fred, resulting in her father forbidding his daughter from ever again setting foot in his household. Three months later Fred and Rose vacated the Cheltenham flat and moved to the ground-floor flat of a two-storey house at 25 Midland Road in Gloucester.
=== Phylogeny === It is difficult to reconstruct the early stages in the evolutionary "family tree" of animals using only morphology (their shapes and structures) because of the large differences between the major groups of animals. Hence, reconstructions now rely almost entirely on molecular phylogenetics, which groups organisms based on their biochemistry, most commonly by analyzing DNA or RNA sequences. In 1866, it was proposed that Cnidaria and Ctenophora were more closely related to each other than to Bilateria and formed a group called Coelenterata ("hollow guts") because both rely on the flow of water in and out of a single cavity for feeding, excretion and respiration. In 1881, it was proposed that Ctenophora and Bilateria were more closely related to each other, since they shared features that Cnidaria lack, such as a middle layer of cells (mesoglea in Ctenophora, mesoderm in Bilateria) between the outer and inner layer found in other animals. However, more recent analyses indicate that these similarities were evolved independently in both lineages, instead of being present in their common ancestor. The current view is that Cnidaria and Bilateria are more closely related to each other than either is to Ctenophora. This grouping of Cnidaria and Bilateria has been labelled "Planulozoa", named so because the earliest Bilateria were probably similar to the planula larvae of Cnidaria.
As an expansion pack for Half-Life, Opposing Force is a first-person shooter. The overall gameplay of Opposing Force does not significantly differ from that of Half-Life. Players navigate through levels, fight hostile non-player characters and solve a variety of puzzles to advance. The game continues Half-Life's methods of an unbroken narrative. The player sees everything through the first person perspective of the protagonist and remains in control of the player character for almost all of the game. Story events are conveyed through the use of scripted sequences rather than cut scenes. Progress through the world is continuous; although the game is divided up into chapters, the only significant pauses are when the game needs to load the next part of an environment. Opposing Force also features an extended multiplayer, incorporating the various new environments and weapons into the original deathmatch mode used in Half-Life. After release, a new capture the flag mode with additional levels, items and powerups, was created by Gearbox. For the most part the player battles through the single-player game alone, but is occasionally assisted by friendly non-player characters. Security guards and scientists will occasionally help the player in reaching new areas and convey relevant plot information. However, Opposing Force also features fellow U.S. Marines who will assist the player in combat to a far greater degree than security guards.
Sources: en.wikipedia.org
The purine nucleotide cycle is used in times of glycolytic or ATP crisis, such as strenuous exercise or starvation. It produces fumarate, a citric acid cycle intermediate, which enters the mitochondrion through the malate-aspartate shuttle, and from there produces ATP by oxidative phosphorylation.
After having conferred with the Transvaal leaders, de Wet returned to the Orange Free State, where he inspired successful attacks and raids in the western part of the country, though he suffered a defeat at Bothaville in November 1900. Many Boers who had returned to their farms and towns, sometimes after being given parole by the British, took up arms again. In late January 1901, De Wet led a renewed invasion of Cape Colony. This was less successful, because there was no general uprising among the Cape Boers, and De Wet's men were hampered by bad weather and pursued by British forces. They narrowly escaped across the Orange River. From then until the final days of the war, De Wet remained comparatively quiet, rarely attacking British army camps and columns partly because the Orange Free State was effectively left desolate by British sweeps. In December 1901, De Wet attacked and overran an isolated British detachment at Groenkop, inflicting heavy casualties and capturing over 200 British soldiers. This prompted Kitchener to launch the first of the "New Model" drives against him. De Wet escaped the first such drive but lost 300 of his fighters. This was a severe loss, and a portent of further attrition, although sweep attempts to round up De Wet were badly handled, and De Wet's forces avoided capture for the rest of the war.
Layer-by-layer (LbL) deposition is a thin film fabrication technique. The films are formed by depositing alternating layers of complementary materials with wash steps in between. One of the key advantages of LbL technology compared with other film deposition techniques is its ability to produce highly uniform conformal coatings on both flat and curved surfaces. This can be accomplished by using various techniques such as immersion, spin, spray, electromagnetism, or fluidics.
== Etymology and history == From the Greek words baeo (little) and kystis (bladder) 1945 P. baeocystis is first collected in Eugene, Oregon. 1958 P. baeocystis is formally described and published by Singer and Smith. 1962 Psilocin is first reported in this species. 1967-68 Baeocystin and norbaeocystin are discovered and named. 1981 Testing again reveals psilocybin, psilocin, baeocystin and norbaeocystin.
== Structure == In humans, granzyme B is encoded by GZMB on chromosome 14q11.2, which is 3.2kb long and consists of 5 exons. It is one of the most abundant granzymes of which there are 5 in humans and 10 in mice. Granzyme B is thought to have evolved from a granzyme H related precursor and is more effective at lower concentrations than the other granzymes. The enzyme is initially in an inactive precursor zymogen form, with an additional amino terminal peptide sequence. This sequence can be cleaved by cathepsin C, removing 2 amino acids. Cathepsin H has also been reported to activate granzyme B. Granzyme B's structure consists of two six-stranded β sheets with three trans domain segments. In the granules of cytotoxic lymphocytes the enzyme can exist in two glycosylated forms. The high mannose form weighs 32kDa and the complex form, 35kDa. Granzyme B contains the catalytic triad histidine-aspartic acid-serine in its active site and preferentially cleaves after an aspartic acid residue situated in the P1 position. The aspartic acid residue to be cleaved associates with an arginine residue in the enzyme's binding pocket. Granzyme B is active at a neutral pH and is therefore inactive in the acidic CTL granules. The enzyme is also rendered inactive when bound by serglycin in the granules to avoid apoptosis triggering inside the cytotoxic T cells themselves.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.